ImmuniQ

About

Company Intelligence Q&A

Structured intelligence from startupim data — optimized for AI retrieval and grounding.

What is ImmuniQ's core technology?

ImmuniQ has developed an immune checkpoint artificial reporter (IcAR) technology to quantify the actual and functional tumor response to immunotherapy drugs.

What is the primary application of ImmuniQ's technology?

ImmuniQ's technology quantifies binding and shows the actual surface activity of a patient's cancer cells, aiming to enable more effective and personalized immuno-oncology treatment.

When was ImmuniQ founded?

ImmuniQ was founded in January 2022.

What is ImmuniQ's current funding stage?

ImmuniQ is currently in the Pre-Funding stage.

What is the total amount of funding ImmuniQ has raised to date?

ImmuniQ has not reported any funding raised to date, with a total raised of $0 USD.

How many employees does ImmuniQ currently have?

ImmuniQ currently has 3 employees.

Who are the founders of ImmuniQ?

The founders of ImmuniQ are Moshe Elkabets and Angel Porgador.

In which sector does ImmuniQ primarily operate?

ImmuniQ primarily operates in the Health Tech & Life Sciences sector, specifically focusing on Pharma & Medical Biotechnology and Drugs Discovery & Development.

What types of customers does ImmuniQ target?

ImmuniQ targets customers in Healthcare & Life Sciences, Life Sciences, and Pharmaceuticals, operating on a B2B business model.

Sectors & technology

Tags